Victoria Bierman
Psychiatric/Mental Health · Blacksburg, VANPI 1407810484
Payments from drug & device makers
Across 110 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$346
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$297
- Braeburn Inc.$261
- Teva Pharmaceuticals USA, Inc.$233
- E.r. Squibb & Sons, L.L.C.$228
- Neurocrine Biosciences, Inc.$216
- plus $855 from 11 others
What the payments were for
- Food & beverage$2,437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $346 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $297 |
| Braeburn Inc. | 11 | $261 |
| Teva Pharmaceuticals USA, Inc. | 9 | $233 |
| E.r. Squibb & Sons, L.L.C. | 9 | $228 |
| Neurocrine Biosciences, Inc. | 10 | $216 |
| Lundbeck LLC | 11 | $190 |
| AbbVie | 7 | $127 |
| Alkermes, Inc. | 7 | $116 |
| Vanda Pharmaceuticals Inc. | 6 | $111 |
| Corium, LLC | 4 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Indivior Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$140
- UZEDY$101
How this compares
$2,437 in reported general payments places this provider in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $102,536 |
| Invega SustennaPaliperidone Palmitate | 29 | $94,966 |
| VraylarCariprazine Hcl | 46 | $63,845 |
| VivitrolNaltrexone Microspheres | 11 | $20,015 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,113 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $7,072 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,957 |
| Lisdexamfetamine Dimesylate | 12 | $3,335 |
| Atomoxetine Hcl | 18 | $2,279 |
| Quetiapine Fumarate | 86 | $1,765 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 18 | $1,747 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $1,549 |
| Divalproex Sodium | 52 | $1,538 |
| Haloperidol Decanoate | 17 | $1,293 |
| Olanzapine | 80 | $1,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $216 | $102,53613 claims |
| Johnson & JohnsonInvega Sustenna | $346 | $94,96629 claims |
| AbbVieVraylar | $127 | $63,84546 claims |
| Alkermes, Inc.Vivitrol | $116 | $20,01511 claims |
| Axsome Therapeutics, Inc.Auvelity | $26 | $13,11312 claims |
| Indivior Inc.Suboxone | $65 | $7,07216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Blacksburg
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.